OPKO Health (NASDAQ:OPK) Hits New 12-Month High Following Analyst Upgrade

Posted by George Bondi on Oct 16th, 2026

OPKO Health, Inc. (NASDAQ:OPK – Get Free Report)’s stock price hit a new 52-week high during trading on Friday after Barrington Research upgraded the stock from a market perform rating to an outperform rating. Barrington Research now has a $2.25 price target on the stock. OPKO Health traded as high as $1.77 and last traded at $1.6850, with a volume of 3,138,029 shares changing hands. The stock had previously closed at $1.61.

OPK has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. Finally, Zacks Research upgraded shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1.93.

Get Our Latest Analysis on OPK

Key OPKO Health News

Here are the key news stories impacting OPKO Health this week:

Positive Sentiment: Labcorp agreed to acquire select assets of OPKO’s wholly owned BioReference Health subsidiary for $722 million in cash, with potential earnout payments bringing the total value to as much as $872 million. The assets include specialty testing in women’s health and a prostate-cancer risk assessment test. The proceeds could strengthen OPKO’s balance sheet and provide capital for its biopharma pipeline. Labcorp agrees to buy BioReference assets for $722 million plus earnout
Positive Sentiment: The asset sale marks a strategic shift for OPKO Health toward its biopharmaceutical business, potentially simplifying the company and allowing management to concentrate resources on higher-growth therapies. News of the deal drove strong buying interest in OPK shares. Labcorp Agrees to Acquire BioReference Assets
Positive Sentiment: Barrington Research upgraded OPK from “Market Perform” to “Outperform” and set a $2.25 price target, implying approximately 40% upside from the referenced $1.61 level. The upgrade likely reinforces sentiment that the transaction improves OPKO’s valuation and financial flexibility. Barrington upgrades OPKO Health to Outperform

Institutional Investors Weigh In On OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. BlackRock Inc. bought a new stake in shares of OPKO Health in the 2nd quarter valued at about $55,468,000. AWM Investment Company Inc. bought a new position in shares of OPKO Health during the second quarter worth about $3,165,000. Bank of New York Mellon Corp bought a new position in shares of OPKO Health during the second quarter worth about $1,995,000. Bank of America Corp DE raised its position in shares of OPKO Health by 80.0% during the first quarter. Bank of America Corp DE now owns 1,141,849 shares of the biotechnology company’s stock worth $1,302,000 after acquiring an additional 507,590 shares during the last quarter. Finally, OP Asset Management Ltd acquired a new position in shares of OPKO Health in the first quarter worth approximately $1,257,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Performance

The stock has a 50 day moving average of $1.52 and a 200 day moving average of $1.37. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -18.28 and a beta of 1.51.

OPKO Health (NASDAQ:OPK – Get Free Report) last released its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The business had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. During the same quarter in the prior year, the firm posted ($0.19) EPS. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, analysts predict that OPKO Health, Inc. will post -0.23 EPS for the current year.

About OPKO Health

(Get Free Report)

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.